- Jun 07, 2023 Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
- Jun 05, 2023 Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients
- May 08, 2023 Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
- Apr 25, 2023 Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference
- Apr 24, 2023 Foghorn Therapeutics Provides an Update on FHD-609
- Apr 10, 2023 Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual Meeting
- Apr 06, 2023 Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting
- Mar 09, 2023 Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
- Mar 01, 2023 Foghorn Therapeutics to Participate at Cowen’s 43rd Annual Health Care Conference
- Jan 09, 2023 Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023
Displaying 11 - 20 of 20